Overview

On 9 June 2010, orphan designation (EU/3/10/749) was granted by the European Commission to NovImmune B.V., the Netherlands, for recombinant human anti-interferon gamma monoclonal antibody for the treatment of haemophagocytic lymphohistiocytosis.

This medicine is now known as emapalumab.

The sponsorship was transferred to Swedish Orphan Biovitrum AB (publ), Sweden, in June 2019.

Haemophagocytic lymphohistiocytosis (HLH) is a disease in which the body produces too many histiocytes and lymphocytes (cells of the immune system), which accumulate in the body's tissues and organs, including the liver, spleen, bone marrow, brain and skin. This causes the symptoms of the disease, such as fever, an enlarged liver and spleen, skin rash, jaundice (yellowing of the skin and eyes) and pancytopenia (low blood cell counts).

HLH is a debilitating and life-threatening disease that is associated with poor long-term survival.

At the time of designation, HLH affected less than 0.1 in 10,000 people in the European Union (EU)*. This is equivalent to a total of fewer than 5,000 people, and is below the threshold for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 27), Norway, Iceland and Liechtenstein. This represents a population of 506,500,000 (Eurostat 2010).

At the time of designation, no satisfactory methods were authorised in the EU for the treatment of HLH. Patients were treated with immunosuppressant medicines (medicines that reduce the activity of the immune system) and chemotherapy (medicines to treat cancer). In some cases, bone marrow transplantation has cured the disease. This is a complex procedure where the bone marrow of the patient is destroyed and replaced with healthy bone marrow from a matched donor.

Recombinant human anti-interferon gamma monoclonal antibody is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a substance called interferon gamma. Patients with HLH have high levels of interferon gamma, which is thought to be responsible for the accumulation of the immune cells causing the disease. By attaching to interferon gamma, this medicine is expected to block its activity, improving the symptoms of HLH.

The effects of recombinant human anti-interferon gamma monoclonal antibody have been evaluated in experimental models.

At the time of submission of the application for orphan designation, no clinical trials with recombinant human anti-interferon gamma monoclonal antibody in patients with HLH had been started.

At the time of submission, recombinant human anti-interferon gamma monoclonal antibody was not authorised anywhere in the EU for HLH or designated as an orphan medicinal product elsewhere for this condition.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 3 March 2010 recommending the granting of this designation.

  • the seriousness of the condition,
  • the existence of alternative methods of diagnosis, prevention or treatment and
  • either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

EU/3/10/749: Public summary of positive opinion for Recombinant human anti-interferon gamma monoclonal antibody for the treatment of haemophagocytic lymphohistiocytosis

AdoptedReference Number: EMA/COMP/164768/2010

English (EN) (118.45 KB - PDF)

First published: Last updated:
View

Key facts

Active substance
Recombinant human anti-interferon gamma monoclonal antibody (emapalumab)
Intended use
Treatment of haemophagocytic lymphohistiocytosis
Orphan designation status
Positive
EU designation number
EU/3/10/749
Date of designation
Sponsor

Swedish Orphan Biovitrum AB (publ)
SE 112 76 Stockholm
Sweden
E-mail: info@sobi.com

EMA list of opinions on orphan medicinal product designation

EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Share this page